Folgen
Giovanni Crisafulli, PhD
Giovanni Crisafulli, PhD
Bioinformatics Manager, Computational Scientist, IFOM, University of Turin,
Bestätigte E-Mail-Adresse bei ircc.it
Titel
Zitiert von
Zitiert von
Jahr
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
11602015
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ...
Nature 552 (7683), 116-120, 2017
6282017
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ...
Cancer discovery 6 (2), 147-153, 2016
4252016
Adaptive mutability of colorectal cancers in response to targeted therapies
M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ...
Science 366 (6472), 1473-1480, 2019
3772019
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer
M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ...
Cancer discovery 6 (1), 36-44, 2016
3142016
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
2982015
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ...
Nature communications 7 (1), 13665, 2016
2152016
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ...
Nature Medicine 28 (8), 1612-1618, 2022
1562022
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ...
Cancer Cell 34 (1), 148-162. e7, 2018
1492018
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ...
Cancer research 76 (15), 4504-4515, 2016
1202016
Werner helicase is a synthetic-lethal vulnerability in mismatch repair–deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy
G Picco, CM Cattaneo, EJ van Vliet, G Crisafulli, G Rospo, S Consonni, ...
Cancer Discovery 11 (8), 1923-1937, 2021
802021
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio, A Amatu, ...
Cancer Discovery 12 (7), 1656-1675, 2022
752022
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
G Mauri, PP Vitiello, A Sogari, G Crisafulli, A Sartore-Bianchi, S Marsoni, ...
British Journal of Cancer 127 (3), 394-407, 2022
702022
Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor
F Orzan, F De Bacco, G Crisafulli, S Pellegatta, B Mussolin, G Siravegna, ...
Stem cells 35 (11), 2218-2228, 2017
672017
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO 3 fusions
G Picco, C Petti, A Centonze, E Torchiaro, G Crisafulli, L Novara, ...
EMBO molecular medicine 9 (3), 293-303, 2017
652017
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
G Siravegna, E Geuna, B Mussolin, G Crisafulli, A Bartolini, D Galizia, ...
Esmo Open 2 (4), e000253, 2017
612017
A genomic analysis workflow for colorectal cancer precision oncology
G Corti, A Bartolini, G Crisafulli, L Novara, G Rospo, M Montone, ...
Clinical colorectal cancer 18 (2), 91-101. e3, 2019
442019
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
G Crisafulli, B Mussolin, A Cassingena, M Montone, A Bartolini, L Barault, ...
ESMO open 4 (6), e000572, 2019
442019
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016; 6: 36–44. doi: 10.1158/2159-8290
M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ...
CD-15-0940.[Abstract][CrossRef][Google Scholar], 0
44
Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
G Siravegna, A Sartore-Bianchi, B Mussolin, A Cassingena, A Amatu, ...
Annals of Oncology 28 (6), 1302-1308, 2017
402017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20